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Basis for Improved Permeability Barrier Homeostasis
Induced by PPAR and LXR Activators: Liposensors
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and Post-Secretory Lipid Processing
Mao-Qiang Man1, Eung-Ho Choi1, Matt Schmuth1, Debra Crumrine1, Yoshikazu Uchida1, Peter M. Elias1,
Walter M. Holleran1 and Kenneth R. Feingold1,2
Previously, we demonstrated that topical applications of peroxisome proliferator-activated receptors (PPARs)
and liver X receptor (LXR) activators improve permeability barrier homeostasis. We showed further that
stimulation of epidermal differentiation provides one mechanism that could account for such improvement.
Here, we studied the effects of these agents on the lipid matrix of the stratum corneum. Hairless mice were
treated topically with activators of PPARa (WY14643), PPARd (GW1514), PPARg (ciglitazone), and LXR (22(R)-
cholesterol or TO901317) or vehicle twice daily for 3 days. All activators significantly increased epidermal
cholesterol, fatty acid, and sphingolipid synthesis, including the production of barrier-specific ceramide
species. In addition, lamellar body (LB) formation, secretion, and post-secretory processing accelerated
significantly following acute barrier disruption in PPAR/LXR-activator-treated animals. Finally, the activity of
epidermal b-glucocerebrosidase, a key lipid-processing enzyme, increased in PPAR/LXR-activator-treated
animals. Thus, topical PPAR and LXR activators stimulate epidermal lipid synthesis, increase LB secretion, and
accelerate extracellular lipid processing, providing additional mechanisms that further account for their ability
to improve epidermal permeability barrier homeostasis. Since the liposensors are activated by endogenous
lipid metabolites, they may serve as unique regulators of barrier homeostasis.
Journal of Investigative Dermatology (2006) 126, 386–392. doi:10.1038/sj.jid.5700046; published online 22 December 2005
INTRODUCTION
A major function of the epidermis is to provide a permeability
barrier. To fulfill this function, keratinocytes undergo a
complex pathway of differentiation, which culminates in
keratinocyte cornification (Fuchs, 1990; Eckert et al., 1997),
which provides both the mechanical strength of the stratum
corneum (SC) as well as a scaffold necessary for the post-
secretory organization of extracellular lipids into a lamellar
matrix. Supported by corneocytes, these lipid-enriched
lamellar membranes are the primary structure responsible
for the permeability barrier to water and electrolyte transit
(Elias and Menon, 1991; Madison, 2003).
The extracellular lamellar membranes of the SC form
following the exocytosis of lamellar bodies (LB) from outer
stratum granulosum (SG) cells (Elias and Menon, 1991; Mao-
Qiang et al., 1995). In order for SG cells to form LB, three
families of lipids, that is, cholesterol, fatty acids, and
ceramides (Cers), must be generated at sufficient levels (Elias
and Feingold, 1992). Moreover, these lipids must be
produced in an approximately equimolar ratio, or abnormal
organelle contents are formed and barrier dysfunction results
(Man et al., 1996).
Studies over the last two decades have demonstrated that
the epidermis is a very active site of lipid synthesis, and
further that inhibition of cholesterol, fatty acid, or Cer
synthesis blocks LB formation (Feingold et al., 1990; Holleran
et al., 1991; Mao-Qiang et al., 1993). Following acute
disruption of the permeability barrier by either detergents,
acetone treatment, or tape stripping, both immediate
exocytosis of preformed LB and accelerated secretion of
newly formed LB occur from SG cells, which leads to the
rapid restoration of lamellar membranes in the extracellular
spaces of the SC (Menon et al., 1992). Epidermal cholesterol
and fatty acid synthesis increases in parallel, providing the
substrates required for additional LB formation. Thus,
epidermal lipid synthesis provides cholesterol, fatty acids,
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and Cers for the formation of LB, which are then secreted,
forming the extracellular lamellar membranes that mediate the
permeability barrier. Finally, the extracellular processing of
secreted lipids is essential for the formation of mature lamellar
membranes and normal permeability barrier function. Inhibi-
tion of either b-glucocerebrosidase or acidic sphingomyeli-
nase, which converts glucosylceramides and sphingomyelin
to Cers, respectively, results in immature lamellar membranes
and defective barrier homeostasis (Holleran et al., 1993;
Jensen et al., 1999). Moreover, patients with either severe
Gaucher’s disease or Niemann–Pick disease, or their murine
transgenic analogues, display comparable abnormalities in
lamellar membrane structure and barrier function (Holleran
et al., 1994; Schmuth et al., 2000).
The peroxisome proliferator-activated receptors (PPARs)
and liver X receptor (LXR) belong to a subset of the nuclear
hormone receptor superfamily (class II receptors), which
heterodimerize with the retinoid X receptor (RXR) (Mangels-
dorf and Evans, 1995; Kersten et al., 2000; Chawla et al.,
2001). PPARs are activated by certain fatty acids, fatty acid
metabolites, and isoprenoids, while LXR is activated by
selected oxysterols (Schoonjans et al., 1996; Forman et al.,
1997; Hanley et al., 2000a; Chawla et al., 2001). As
endogenous lipids activate PPARs and LXR, they are
considered to be ‘‘liposensors’’, which, in turn, regulate
organ-specific pathways of lipid metabolism. Recent studies
have shown that activators of PPARa, PPARb/d, PPARg, and
LXR accelerate permeability barrier recovery following acute
barrier disruption (Komuves et al., 2000, 2002; Mao-Qiang
et al., 2004; Schmuth et al., 2004b). One mechanism that
could account for their positive effects on barrier function
clearly relates to stimulation of epidermal differentiation.
Both in cultured human keratinocytes treated with PPAR and
LXR activators, and following topical applications of PPAR
and LXR activators to normal mouse skin, loricrin, filaggrin,
involucrin, and transglutaminase 1 expression increase
(Komuves et al., 2000, 2002; Mao-Qiang et al., 2004;
Schmuth et al., 2004b; Hanley et al., 1998, 2000b).
The purpose of the present study was to determine
whether the acceleration of barrier recovery can be attributed
not only to the well-known effects of these liposensors on
epidermal differentiation but also to additional stimulation of
components of the extracellular matrix. Our studies show that
these agents stimulate lipid synthesis, accelerate LB secretion,
and stimulate the extracellular processing of secreted lipids
into mature extracellular membrane structures.
RESULTS
Structural basis for the PPAR and LXR activator-induced
improvement in barrier function
To determine the mechanism for the increase in barrier
recovery following acute disruption, using electron micro-
scopy we initially examined the effects of 3 days of topical
treatment of normal hairless mice with PPARa, PPARb/d,
PPARg, and LXR activators on the LB secretory system, and on
the extracellular lamellar matrix of the SC. While the density
of LB in the cytosol of SG cells did not change following
either PPAR or LXR activator treatment, secretion of organelle
contents from SG cells occurred prematurely following
treatment with PPARa, PPARb/d, and LXR activators (but
not following treatment with PPARg activators) (Table 1;
Figure 1b vs a). Specifically, LB are largely secreted at the
apical surface of outer SG cells; that is, at the SG–SC interface
in vehicle-treated, control epidermis. In contrast, in PPARa-,
PPARb/d-, and LXR- but not PPARg-activator-treated animals,
LB secretion begins much earlier in differentiation; that is,
several, nucleated cell layers subjacent to the SG–SC inter-
face (Figure 1c vs a). These features are present not only prior
to barrier disruption, but premature secretion was also
evident at various time points after acute barrier disruption;
again, PPARg activators did not appear to alter LB secretion
under comparable conditions (Table 1). Of note is that the
internal membrane structure of LB was similar in control and
PPAR/LXR-treated samples, suggesting that the lipid compo-
Table 1. Influence of liposensor activators on basal
lamellar body production and secretion changes with
liposensor vs vehicle
Parameter PPARa PPARc PPARb/d LXR
Basal
LB density No change1 No change No change No change
LB contents No change No change1 No change No change
LB secretion Premature Slight m
(premature)
Premature Premature
Post-barrier disruption
LB secretion Accelerated2 No change2 Accelerated2 Accelerated2
Extracellular
lamellae
Increased3 Slight m Increased Increased
1No change=liposensor-treated is comparable to vehicle-treated control.
2Post-tape stripping acceleration of secretion in liposensor- versus
vehicle-treated controls.
3Refers to number of membrane leaflets between adjacent corneocytes.
Figure 1. Liposensor activators accelerate secretion of LB. Skin samples
were from mice treated twice daily (b, c) with PPAR or LXR activators or
(a) vehicle alone for 3 days. (a, b) Arrowheads demonstrate differences in
the amount of secreted LB contents at the SG–SC interface in vehicle-treated
controls (Co) versus LXR-treated epidermis under basal conditions.
(c) (PPARb/d-treated): Arrowheads demonstrate secretion of LB contents
between suprabasal keratinocytes several cell layers subjacent to the SC.
Osmium tetroxide post-fixation. Bars¼ 0.5 mm.
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sition was not altered by PPAR/LXR treatment. Finally, the
PPAR- and LXR-treated mice also demonstrated accelerated
maturation of lamellar membranes within the extracellular
spaces of the SC, a change that was most evident within the
first few hours after barrier disruption. While much of the
secreted LB contents in vehicle-treated controls has not yet
been processed into mature lamellar membranes, following
PPAR or LXR activator treatment, secreted LB contents
instead appear fully processed into mature membrane
structures by the first intercellular space above the SG–SC
interface (Figure 2b vs a; Table 1). Together, these results
show that the PPAR (except PPARg) and LXR activators both
accelerate LB secretion and stimulate the post-secretory
maturation of secreted lipids.
Lanthanum nitrate permeates from the dermis toward the
SC through intercellular spaces of the epidermis. It has been
used as a tracer to visualize epidermal permeability barrier
function for years. In the present study, the movement of
lanthanum is blocked at the SC/SG interface in vehicle-treated
intact skin. In contrast, in PPARa-treated intact skin, the
movement of lanthanum is blocked at several nucleated layers
below the SC/SG interface (Figure S1). When barrier function
is perturbed by tape stripping, abundant tracer is seen in SC
in vehicle-treated skin, but little is seen in the PPARa-treated
sample (Figure S2). These results suggest that the prematurely
secreted LB that occur in PPARa-treated animals are
functional and provide a barrier to the movement of the
water-soluble tracer lanthanum nitrate.
Lipid biochemical basis for PPAR- and LX-induced improvement
in barrier function
The formation of epidermal LB requires production of lipids,
primarily derived from epidermal lipid synthesis. Therefore,
we next determined whether treatment with PPARa, PPARb/
d, PPARg, and LXR activators (two chemically unrelated LXR
activators were employed, TO-901317 and 22R-OH-choles-
terol) for 3 days would stimulate epidermal lipid synthesis. All
four classes of liposensors, including both the LXR activators,
significantly increased the incorporation of [14C]acetate into
cholesterol, total nonsaponifiable lipids (cholesterol, lanos-
terol, squalene, and other precursors of cholesterol), and fatty
acids (Figure 3a–d; data for 22(R)-OH-cholesterol not shown).
Moreover, PPARa-, PPAR, and LXR (but not PPARg) activators
stimulated total sphingolipid synthesis. Thus, stimulation of
epidermal lipid synthesis by PPAR and LXR activators could
account for accelerated LB secretion by providing the bulk
lipids required for additional LB formation.
To assess more specifically whether the elevations in total
sphingolipid synthesis reflect increased production of barrier-
specific Cer species, we determined the effect of one of
the nuclear hormone receptor activators (GW1514, which
activates PPARd) on both acylCer (Cer 1; omega-esterified,
sphingosine-containing Cer) and its glucosylated precursor,
acylglucosylCer (AcylGlcCer). Treatment of murine skin for 3
days with GW1514 significantly increased both total GlcCer
and AcylGlcCer synthesis (Figure 4), with elevated AcylGlcCer
production being equivalent to that for all other GlcCer
species; that is, approximately three- to four-fold increases over
vehicle-treated epidermis. Similarly, the increased AcylCer
production was equivalent to or higher than that observed for
other Cer species; that is, 5.3-fold vs 6.4- and 4.0-fold for
AcylCer versus Cer 2 (nonhydroxy, sphingosine-containing
Cer) and Cer3-7 species, respectively. These data reveal that
the GW1514-induced increases in sphingolipid production
include significant elevations in barrier-related Cer species.
PPAR and LXR activators stimulate the extracellular processing
of secreted lipids
LB secrete not only lipids but also a family of lipid-processing
enzymes, including b-glucocerebrosidase, required for the
Figure 2. Liposensor activators accelerate maturation of secreted LB
contents. Skin samples were taken at 3 hours after tape stripping from mice
treated with liposensor activators or vehicle. (a) In vehicle-treated control
epidermis (Co), secreted LB contents are not yet fully processed into mature
lamellar membranes (open arrows). (b) Liposensor-treated skin sites (LXR
results shown) after barrier disruption reveal accelerated maturation of
secreted LB contents (closed arrows). Ruthenium tetroxide post-fixation.
Bars¼ 0.25 mm.
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Figure 3. PPAR and LXR activators stimulate epidermal lipid synthesis.
Hairless mice were treated with 10 mM WY14643 (a – PPARa activator), 4 mM
GW1514 (b – PPARb/d activator), 10 mM ciglitazone (c – PPARg activator),
10 mM TO901317 (d – LXR activator), or vehicle alone twice daily for 3 days.
The epidermis was incubated with 40mCi acetate for 2 hours at 371C and the
incorporation into sphingolipids was determined as described in Materials
and Methods. Data are expressed as percent of control and are mean7
standard error of the mean. N¼6–10 for groups.
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extracellular conversion of glucosylceramides to Cers in the
SC, an essential step in the formation of mature, functional
lamellar membranes. Pretreatment with PPARa, PPARb/d,
PPARg, and LXR (again two chemically unrelated LXR
agonists) activators all increased total b-glucocerebrosidase
activity assessed in an in vitro fluorescence assay at pH 5.6,
the enzyme’s pH optimum (Figure 5). Next, to determine
whether this increase in activity occurs in sites where lipid
processing into mature membrane structures normally
occurs, we used in situ zymography to visualize the changes
in b-glucocerebrosidase activity in frozen sections of
liposensor- versus vehicle-treated skin. As shown in
Figure S3, the increase in b-glucocerebrosidase activity that
is induced by PPAR and LXR activators occurs in the outer
epidermis: more specifically, largely in the outer SG and
within the lower layers of the SC. This highly localized
increase in b-glucocerebrosidase, induced by PPAR and LXR
activators, may account for the rapid extracellular production
of mature lamellar membrane structures in the extracellular
spaces of activator-treated SC (cf. Figure 2).
DISCUSSION
Previous studies demonstrated that topical treatment with all
three types of PPAR, as well as LXR activators, all accelerate
permeability barrier recovery following acute barrier disrup-
tion (Komuves et al., 2000, 2002; Mao-Qiang et al., 2004;
Schmuth et al., 2004b). However, there were minor
differences in the effects of these agents on barrier function;
for example, while treatment with PPARa, PPARb/d, and LXR
activators accelerated barrier recovery at both 3 and 6 hours,
the PPARg activator only accelerated barrier recovery after
either acetone treatment or tape stripping at the 6-hour time
point (Mao-Qiang et al., 2004). In contrast, none of these
agents altered either SC hydration or the surface pH of the SC
(data not shown).
Epidermal differentiation terminates in the formation of the
SC, a structurally heterogeneous tissue that subserves multi-
ple cutaneous defensive functions. Perhaps the most im-
portant of these functions is to provide a barrier to the
movement of water and electrolytes, the epidermal perme-
ability barrier. While many studies have demonstrated the
importance of the SC’s lipid-enriched, extracellular matrix in
mediating the permeability barrier, less well appreciated is
the role of the corneocyte for this function (White et al.,
1988; Nemes and Steinert, 1999; Harding, 2004). Biophysi-
cal studies have shown that corneocytes force water
molecules to traverse a torturous, elongated pathway
(‘‘spacer function’’). But perhaps more important, the
corneocytes provide a scaffold for the supermolecular
organization of the lipid matrix into stacks of broad, highly
organized, lamellar membranes. The critical role of the
corneocytes in membrane formation is demonstrated most
convincingly in two genetic disorders, transglutaminase 1-
deficient lamellar ichthyosis (Elias et al., 2002) and Vohwin-
kel’s disease (loricrin keratoderma) (Schmuth et al., 2004a),
where a defective cornified envelope leads to profound
alterations in extracellular lamellar membrane organization.
Thus, the quality of the corneocyte ‘‘brick’’ clearly is
important for permeability barrier homeostasis, and activa-
tion of PPARs and LXR has been shown to stimulate the
differentiation of several constituents of the corneocyte
envelope. For example, activators of PPARa, PPARb/d,
PPARg, and LXR stimulate keratinocyte differentiation and
the formation of the cornified envelope in cultured human
keratinocytes, rodent skin in uteral, normal rodent epidermis,
murine models of hyperproliferative skin, and even in
psoriasis in humans (Hanley et al., 1997, 1998, 2000a, b;
Komuves et al., 1998, 2000, 2002; Ellis et al., 2000;
Westergaard et al., 2001). Finally, activators of PPARa,
PPARb/d, PPARg, and LXR accelerate the return of perme-
ability barrier function toward normal following acute barrier
disruption (Komuves et al., 2000, 2002; Mao-Qiang et al.,
2004; Schmuth et al., 2004b). However, until the studies
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Figure 4. PPARd activator also increases barrier-related specific Cer
synthesis. Hairless mice were treated with PPARd activator (GW1514) or
vehicle for 3 days. The epidermis was isolated, incubated with 40 mCi acetate
for 2 hours at 371C, and the incorporation into lipids was determined as
described in Materials and Methods. Data are expressed as percent of vehicle-
treated control (set to 100%) and are the meanþ standard error of the mean.
n¼ 4 for each value; in each case, Po0.001 for GW1514 versus vehicle-
treated values.
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Figure 5. PPAR and LXR activators stimulate b-glucocerebrosidase activity.
Hairless mice were treated with PPAR, LXR activators or vehicle for 3 days.
Epidermis from both activator and vehicle-treated animals were obtained by
EDTA separation. Epidermal homogenate were incubated with 4-methylum-
belliferone-b-D-glucoside for 90 minutes at 371C. Fluorescence was measured
at 360 nm/450 nm. Results are expressed as percent of control and are
meanþ standard error of the mean. One-way ANOVA was used to determine
the statistic significance (*Po0.01), n¼12–20 for groups.
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described here, the improvement in permeability barrier
homeostasis, induced by treatment with PPAR and LXR
activators, was attributed solely to the well-recognized effects
of these agents on corneocyte formation. Although PPARa
activators stimulate lipid synthesis in human epidermal
organotypic cultures (Rivier et al., 2000), little attention has
been accorded to the potential additional role of PPAR and
LXR activation in regulating the formation and organization
of the extracellular lipid matrix.
In the present study, we demonstrate that activators of
PPARa, PPARb/d, PPARg, and LXR stimulate all three key steps
in lipid matrix formation; that is, epidermal lipid synthesis, LB
secretion, as well as the activity of b-glucocerebrosidase, an
enzyme required for the extracellular processing of secreted LB
contents. Premature LB secretion, that is, below the SC and SG
interface, occurs after topical application to normal murine skin
alone and following acute barrier disruption. Interestingly,
while in control animals almost all LB are secreted from the
apical surface of cells at the SG–SC interface, in PPARa-,
PPARb/d-, and LXR-activator-treated animals, secretion of LB
occurs in a premature fashion between nucleated cells several
layers beneath the SG–SC interface. Moreover, this prematurely
secreted lamellar material has a permeability function demon-
strated by its ability to impede the movement of lanthanum. The
contribution of this lamellar material to total permeability
function is currently unknown. Additionally, in both the basal
state and following barrier disruption, increased LB secretion at
the SC/SG interface occurs in PPAR/LXR-treated animals, which
probably contributes to the accelerated recovery in barrier
function. Furthermore, with the exception of the failure of
PPARg activators to increase Cer synthesis, the synthesis of all
three classes of lipids required for LB formation, that is,
cholesterol, free fatty acids, and Cers, increase after treatment
with PPAR and LXR activators. Finally, an increase in total b-
glucocerebrosidase activity, which further localized specifically
to the outer nucleated layers of the epidermis and lower SC,
was also induced by treatment with all of the liposensor
activators. Thus, in addition to stimulating corneocyte forma-
tion, PPAR and LXR activators also stimulate all three steps
(synthesis, secretion, extracellular lipid processing) required for
the formation of the extracellular lamellar lipid matrix of the SC.
The somewhat different findings with PPARg activators are
worth noting. Specifically, previous studies demonstrated that
PPARg activators are less effective than the other liposensor
activators in improving permeability barrier homeostasis
(Mao-Qiang et al., 2004). This observation fits well with the
observation here that the PPARg activator only minimally
stimulated LB secretion, and failed to significantly stimulate
Cer synthesis, a key lipid component of the extracellular
matrix. These differences resonate with other variations in
impact within the class II family of nuclear hormone
receptors. Classic activators of members of this family, that
is, retinoids (RAR and RXR activators) and 1, 25 OH vitamin
D (vitamin D receptor), actually display adverse effects
on permeability barrier homeostasis (Elias et al., 1981;
von Brenken, 1997). Moreover, retinoids inhibit, rather than
stimulate, corneocyte protein formation (Green and Watt,
1982; Brown et al., 1994). Thus, the class II nuclear hormone
receptor activators do not always display parallel regulatory
effects on SC structure and function.
The protein (corneocytes – bricks) and lipid (extracellular
lipid matrix – mortar) arms of SC formation are traditionally
viewed as concurrent, but independent, processes. However,
the ability of endogenous lipids to activate PPARs and LXRs
and the abundant data demonstrating that these liposensors
can stimulate keratinocyte proteins required for cornified
envelope formation suggest that there may be crosstalk
between these two parallel arms of keratinocyte differentia-
tion, coordinated by liposensor activation (Hanley et al.,
1998, 2000b; Komuves et al., 2000, 2002; Mao-Qiang et al.,
2004; ; Schmuth et al., 2004b). One can speculate that as
lipid precursors accumulate in SG cells, these lipids or their
metabolites could then serve as endogenous activators of the
liposensor receptors, which, in turn, could stimulate the
differentiation program of suprabasal keratinocytes increasing
the expression of the structural proteins required to form the
cornified envelope. Moreover, we show here that these
liposensors also stimulate the steps required for the formation
of the extracellular lipid matrix, allowing for the coordinated
formation of the SC.
In summary, the present study demonstrates that PPAR
and LXR activators stimulate the three key steps required for
the formation of the extracellular lipid matrix of the SC: LB
secretion, epidermal lipid synthesis, and the activity of lipid-
processing enzymes.
MATERIALS AND METHODS
All animal procedures were approved by the Animal Studies
Subcommittee of the San Francisco Veterans Administration Medical
Center and were performed in accordance with their guidelines.
Materials
Male hairless mice (hr/hr), 6–8 weeks old, were purchased from
Charles Rivers Laboratories (Wilmington, MA) and fed mouse diet
(Ralston-Purina Co., St Louis, MO) and water ad lib. Acetone and
petroleum ether were purchased from Fisher Scientific (Fairlane, NJ).
4-Methylumbelliferone, 4-methylumbelliferone-b-D-glucoside, PPARa
activator WY 14643, and LXR activator 22(R)-hydroxycholesterol
were purchased from Sigma Chemical Co. (St Louis, MO). Another
LXR activator TO901317 and the PPARg activator ciglitazone
were purchased from Cayman Chemical (Ann Arbor, MI). PPARd
activator GW 1514 was a gift from Dr Timothy Willson (Glaxo-
SmithKline, Triangle Park, NC). [14C]acetate (56 mCi/mmol) was
purchased from American Radiolabeled Chemicals, Inc. (St Louis,
MO), and D-glucopyranoside was purchased from Molecular Probes
(Eugene, OR).
Experimental protocols and functional studies
Groups of animals were topically treated with one of the following
agents twice daily, 10 mM ciglitazone, 10 mM 22(R)-hydroxycholes-
terol, 10 mM WY14643, 4 mM GW1514, 10 mM TO901317, or
acetone alone as vehicle-treated control, for 3 days.
Epidermal lipid synthesis
After 3 days treatment, skin samples were incubated for 2 hours at
371C in 2 ml of 10 mM EDTA in calcium- and magnesium-free PBS
390 Journal of Investigative Dermatology (2006), Volume 126
M-Q Man et al.
Basis for PPAR- and LXR-Induced Barrier Improvement
containing 40 mCi [14C]acetate, as described previously (Mao-Qiang
et al., 1993). After stopping the reaction by placing on ice, the
epidermis was separated from the dermis. The incorporation rates of
[14C]acetate into free fatty acids and cholesterol in epidermis were
determined following saponification, extraction, and thin-layer
chromatography, as described previously (Feingold et al., 1990;
Mao-Qiang et al., 1993). For sphingolipid synthesis, the epidermal
lipids were extracted by Bligh–Dyer as described previously
(Holleran et al., 1991). The lipid components were separated by
HPTLC developed in the following solvent mixtures: (1) chloroform/
methanol/water (40:10:1, v/v) for 2 and 5 cm; (2) chloroform/
methanol/acetic acid (47:2:05, v/v) for 8.5 cm; (3) N-hexane/
diethylether/acetic acid (30:15:0.5, v/v) for 9 cm. The corresponding
lipid bands were collected and counted with a scintillation counter.
b-Glucocerebrosidase
Total enzyme activity. Epidermis from both activator- and
vehicle-treated groups was obtained by EDTA separation. b-
Glucocerebrosidase activity was measured as published previously
(Takagi et al., 1999). The activity was expressed as nM/mg protein/
hour.
In situ zymography. Frozen sections of 5mm were washed with
solutions containing 0.025% Tween 20 three times. A volume of
200ml substrate solution containing 5 mM D-glucopyranoside was
added to each section and incubated for 2 hours at 371C. The
sections were visualized with a Zeiss (Axioplan 2) microscope (Jena,
Germany). Digital images were captured with AxioVision software
2.05 (Carl Zeiss Vision, Munich, Germany).
Electron microscopy. Hairless mice were treated twice daily with
PPAR or LXR activators or vehicle alone for 3 days and skin biopsies
were obtained before and three hours after tape stripping. Samples
were fixed in Karnovsky’s fixative overnight, and post-fixed with either
0.25% ruthenium tetroxide or 1% aqueous osmium tetroxide,
containing 1.5% potassium ferrocyanide, as described previously
(Hou et al., 1991). Ultrathin sections were examined after further
contrasting with lead citrate in an electron microscope (Zeiss 10A, Carl
Zeiss, Thornwood, NY) operated at 60 kV. LB density and secretion
were assessed visually in randomly photographed, coded micrographs
by PME without knowing the experimental treatment groups.
Both prior to and 3 hours after tape stripping, intact PPARa-
activator- or vehicle-treated skin samples were obtained and used for
lanthanum tracer studies according to the method described
previously (Elias and Brown, 1978). Briefly, biopsies were floated
on 4% lanthanum solution containing 4% sucrose, 0.05 M cacody-
late, and 1% glutaraldehyde at pH 7.6 for 2 hours and then fixed in
Karnovsky’s fixative overnight, followed by post-fixation in 1%
osmium tetroxide containing 1.5% potassium ferrocyanide. Un-
stained ultrathin sections were visualized with an electron micro-
scope, as stated above.
Statistical analyses. All statistical analyses were performed using
the two-tailed Student’s t-test or one-way ANOVA test. Data were
expressed as mean7standard error of the mean.
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SUPPLEMENTARY MATERIAL
Figure S1. Accelerated lamellar secretion correlates with early blockade of
lanthanum tracer. Hairless mice were treated with either the PPARa activator,
WY14643 (10 mM) or vehicle alone (insert) for 3 days. In vehicle(V)-treated
sample, tracer reaches the SC/SG interface. In PPARa activator-treated samples,
tracer egress is blocked several layers below the SC/SG interface (arrows), at the
levels where LB secretion is accelerated (c.f., Figure 1). Bar¼2mm.
Figure S2. Accelerated lamellar body secretion blocks tracer movement into
sc after tape stripping. Both vehicle and activator treated samples were tape-
stripped (TS). Biopsies were floated on lanthanum for 2 hours. In vehicle (V)-
treated samples, substantial tracer percolates into the SC interstices (arrows),
while little tracer reaches the SC in activator-treated skin samples. Bar¼ 2 mm.
Figure S3. PPAR and LXR activators stimulate b-glucocerebrosidase activity in
the outer epidermis: Hairless mice were treated with PPAR, LXR activators or
vehicle for three days. Frozen sections from both activators and vehicle-
treated groups were incubated with D-glucopyranoside for 2 hours at 371C.
And then the sections were visualized with fluorescence microscopy.
Bar¼1 mm.
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